Two new drugs for advanced skin cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two new drugs—an immunotherapy and an antibody-drug conjugate—for people with advanced squamous cell carcinoma of the skin. The goal is to see if this combo can shrink tumors and slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have a type of skin cancer called cutaneous squamous cell carcinoma that is advanced or has spread, and cannot be removed with surgery
- You have had no more than one prior type of chemotherapy for your cancer
- You are in generally good health, with a performance score of 0 or 1 (meaning you can do most daily activities on your own)
- You have not had immunotherapy or anti-EGFR treatment before
- You can provide a tumor sample (from a previous biopsy or willing to have a new one)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
This trial tests two new drugs (Becotatug vedotin and Pucotenlimab), with or without radiation, as the first treatment for advanced lung cancer that has a specific protein marker (EGFR). The goal is to see if this combination can shrink tumors and help people live longer without their cancer growing.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.